{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:06:25Z","timestamp":1784304385752,"version":"3.55.0"},"reference-count":33,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pharmacosmos UK Ltd"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2020,4,8]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In gastroenterological disorders, iron deficiency (ID) is often treated with intravenous iron. This real-world study assessed the effectiveness and safety of iron isomaltoside (IIM), a high-dose intravenous iron, for the treatment of ID in patients with gastroenterological disorders, as part of a service evaluation and improvement process.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Medical records of 117 patients with gastroenterological disorders, who received IIM, were examined retrospectively. Study outcomes included dose of IIM (estimated iron need versus actual dose received), number of appointments required to deliver the dose and changes in haemoglobin (Hb) and ferritin at ~1\u2009month and ~6 months post-treatment. Safety was assessed through adverse drug reactions (ADRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 76.1% of patients received their estimated iron need; 23.9% were underdosed. The mean (SD) iron dose was 1317 (409.7) mg; 62.4% of patients received their dose in one appointment. From baseline, mean (SD) Hb increased by 20.9 (15.4) g\/L at 1\u2009month post-treatment (p&lt;0.0001) and by 22.0 (17.9) g\/L at 6 months post-treatment (p&lt;0.0001). Mean (SD) baseline ferritin was 26.6 (37.8) \u03bcg\/L, which increased to 234.6 (142.9) \u03bcg\/L at 1\u2009month post-treatment (p&lt;0.0001), and remained increased at 6 months post-treatment (122.8 (99.2) \u03bcg\/L; p&lt;0.0001). A substantial proportion of patients were non-anaemic at 1\u2009month (57.5%) and 6 months (61.8%) post-treatment. At both post-treatment timepoints, the proportion of non-anaemic patients was higher in those receiving their total iron need versus those who were underdosed. No serious ADRs were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IIM was efficacious and well tolerated in patients with gastroenterological disorders. This real-world study highlights the importance of administering the full iron need to maximise treatment response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2020-101406","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T18:11:26Z","timestamp":1589393486000},"page":"265-271","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-5030","authenticated-orcid":false,"given":"Jackie","family":"Kearns","sequence":"first","affiliation":[{"name":"Antrim Area Hospital, Antrim, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer George","family":"Jacob","sequence":"additional","affiliation":[{"name":"Antrim Area Hospital, Antrim, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"2025090708145946000_12.4.265.1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009"},{"key":"2025090708145946000_12.4.265.2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CEG.S43493","article-title":"Iron deficiency anemia in patients with inflammatory bowel disease","volume":"6","author":"Goldberg","year":"2013","journal-title":"Clin Exp Gastroenterol"},{"key":"2025090708145946000_12.4.265.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03146.x"},{"key":"2025090708145946000_12.4.265.4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i22.2720"},{"key":"2025090708145946000_12.4.265.5","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.3748\/wjg.v22.i35.7908","article-title":"Anemia and iron deficiency in gastrointestinal and liver conditions","volume":"22","author":"Stein","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025090708145946000_12.4.265.6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrgastro.2010.151","article-title":"Diagnosis and management of iron deficiency anemia in patients with IBD","volume":"7","author":"Stein","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025090708145946000_12.4.265.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2014.05.001"},{"key":"2025090708145946000_12.4.265.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000235097.86360.04"},{"key":"2025090708145946000_12.4.265.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01744.x"},{"key":"2025090708145946000_12.4.265.10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.228874"},{"key":"2025090708145946000_12.4.265.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.013"},{"key":"2025090708145946000_12.4.265.12","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.335"},{"key":"2025090708145946000_12.4.265.13","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3109\/00365521.2015.1031168","article-title":"A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease","volume":"50","author":"Reinisch","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2025090708145946000_12.4.265.14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/00365521.2016.1196496","article-title":"High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23","volume":"51","author":"Dahlerup","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2025090708145946000_12.4.265.15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman","year":"2017","journal-title":"Am J Hematol"},{"key":"2025090708145946000_12.4.265.16","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4585164","article-title":"The NIMO Scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency","volume":"2017","author":"Frigstad","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"2025090708145946000_12.4.265.17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/00365521.2018.1498914","article-title":"Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice","volume":"53","author":"Stein","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"2025090708145946000_12.4.265.18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090708145946000_12.4.265.19","unstructured":"Monofer\u00ae (iron isomaltoside 1000) . Summary of product characteristics. Pharmacosmos A\/S [Accessed March 2020]."},{"key":"2025090708145946000_12.4.265.20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00365521.2018.1441435","article-title":"Inflammatory bowel disease and anemia: intravenous iron treatment","volume":"53","author":"Kangaspunta","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"2025090708145946000_12.4.265.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005"},{"key":"2025090708145946000_12.4.265.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60865-0"},{"key":"2025090708145946000_12.4.265.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e02045","article-title":"Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations","volume":"5","author":"Rostoker","year":"2019","journal-title":"Heliyon"},{"key":"2025090708145946000_12.4.265.24","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20285"},{"key":"2025090708145946000_12.4.265.25","first-page":"104","article-title":"Management of iron deficiency anemia in inflammatory bowel disease \u2013 a practical approach","volume":"26","author":"Stein","year":"2013","journal-title":"Ann Gastroenterol"},{"key":"2025090708145946000_12.4.265.26","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/763576","article-title":"Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations","volume":"2015","author":"Koch","year":"2015","journal-title":"Anemia"},{"key":"2025090708145946000_12.4.265.27","first-page":"1","article-title":"The importance of dose optimisation in the treatment of iron deficiency in heart failure","author":"Martens","year":"2019","journal-title":"Acta Cardiol"},{"key":"2025090708145946000_12.4.265.28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/CEOR.S139525","article-title":"A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000","volume":"9","author":"Pollock","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025090708145946000_12.4.265.29","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1007\/s12325-018-0827-5","article-title":"An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark","volume":"35","author":"Pollock","year":"2018","journal-title":"Adv Ther"},{"key":"2025090708145946000_12.4.265.30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"2025090708145946000_12.4.265.31","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2018.00125"},{"key":"2025090708145946000_12.4.265.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.10.007"},{"key":"2025090708145946000_12.4.265.33","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/bph.13268","article-title":"Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management","volume":"172","author":"Szebeni","year":"2015","journal-title":"Br J Pharmacol"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2020-101406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:15:10Z","timestamp":1757258110000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2020-101406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/flgastro-2020-101406"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2020-101406","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]}}}